Astrocyte CD38-erk Mapk signaling controls mitochondrial transfer to neurons via Tnt-mediated vesicle trafficking
🧪 Overview
Under neurodegenerative stress, astrocytes upregulate CD38, which triggers Erk MAPK signaling to promote tunneling nanotube (TNT) formation through M-Sec (TNFAIP2) and F-actin remodeling, enabling astrocyte-to-neuron mitochondrial transfer. These transferred mitochondria exhibit enhanced membrane potential and ATP production, restoring neuronal bioenergetics and reducing apoptosis. Disruption of astrocyte CD38 signaling (via CD38 knockout or Erk inhibition) impairs TNT formation and mitochondrial transfer, leading to accelerated neuronal loss in ALS/AD models. This predicts that pharmacologic CD38 agonism or direct administration of astrocyte-derived mitochondria will ameliorate motor/cognitive deficits in rodent neurodegeneration models.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["CD38 Signaling<br/>Erk MAPK Cascade"]
B["TNT Formation<br/>Tunneling Nanotubes"]
C["Mitochondrial Transfer<br/>Astrocyte to Neuron"]
D["Neuronal Viability<br/>Enhanced"]
E["CD38-Erk-TNT Axis<br/>as Neuroprotective Target"]
F["Mitochondrial<br/>Therapy"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CD38
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CD38 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CD38.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF a selective CD38 agonist (e.g.,辞BS11 or apraglutide) is administered daily to SOD1*G93A transgenic mice for 8 weeks starting at disease onset, THEN astrocyte-to-neuron mitochondrial transfer will i | Increased intercellular mitochondrial transfer via TNTs and improved motor performance | — no observation — | pending | 0.65 |
| IF astrocyte-specific Erk MAPK signaling is inhibited (via Cre-lox mediated Map2k1 knockout in GFAP-Cre mice or daily MEK inhibitor PD0325901) in 5xFAD amyloid mouse model, THEN mitochondrial transfer | Reduced mitochondrial transfer and accelerated cognitive decline | — no observation — | pending | 0.58 |
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |